NCT06692452 2026-04-01
Tazemetostat Plus CHOP in 1L T-cell Lymphoma
Dana-Farber Cancer Institute
Phase 2 Withdrawn
Clinical Trials
83 trialsNCT06626256 2025-12-24
STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma
City of Hope Medical Center
Phase 1 Withdrawn
NCT06190249 2025-06-05
LN-144
Case Comprehensive Cancer Center
Phase 1 Withdrawn
NCT06572631 2025-05-25
Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor
City of Hope Medical Center
Phase 1 Withdrawn
NCT02548468 2025-05-02
Reduced Intensity Conditioning Before Partially Matched Donor Stem Cell Transplant in Treating Patients With Advanced Cutaneous T Cell Lymphoma
Thomas Jefferson University
Phase 1 Withdrawn
NCT04418219 2025-04-29
Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer
Thomas Jefferson University
Phase 1/2 Withdrawn
NCT06094842 2025-04-01
Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer
Fred Hutchinson Cancer Center
Phase 1 Withdrawn
NCT05714306 2025-03-05
CHUV-OVACURE
Centre Hospitalier Universitaire Vaudois
Phase 1/2 Withdrawn
NCT06003179 2024-11-12
LOKI
University Health Network, Toronto
Phase 1 Withdrawn
NCT05177796 2024-10-24
Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT01843868 2024-08-07
Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP
Australasian Leukaemia and Lymphoma Group
Phase NA Withdrawn
NCT05950113 2024-05-01
CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma
Jonsson Comprehensive Cancer Center
Phase 1 Withdrawn
NCT05895201 2024-04-29
High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD
Indiana University
Phase 1/2 Withdrawn
NCT04220008 2024-01-12
Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT04029038 2023-08-21
Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT05513612 2023-03-01
Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies
Shanghai Pudong Hospital
Phase 1 Withdrawn
NCT05531708 2023-03-01
Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid Tumors
Shanghai Pudong Hospital
Phase 1 Withdrawn
NCT04282174 2022-09-27
2019-KOE-001
Baptist Health South Florida
Phase 2 Withdrawn
NCT04762901 2022-04-26
LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer
Wake Forest University Health Sciences
Phase 1 Withdrawn
NCT04893915 2022-03-11
Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS
Washington University School of Medicine
Phase 2 Withdrawn
NCT04038489 2021-11-22
Breast 51
University of Virginia
Phase 2 Withdrawn
NCT00006669 2021-10-27
Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma
Medstar Health Research Institute
Phase 2 Withdrawn
NCT02441270 2021-07-13
Evaluation of the Immunological Effects of a Combined Treatment With Radiation and Cyclophosphamide in Metastasized Breast Cancer Patients
University Hospital, Ghent
Phase EARLY_PHASE1 Withdrawn
NCT04067102 2021-07-09
Nab-paclitaxel Based Regimens VS Paclitaxel Based Regimens in Neoadjuvant Treatment for TNBC
Hebei Medical University Fourth Hospital
Phase NA Withdrawn
NCT03602898 2021-06-30
Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation
Fred Hutchinson Cancer Center
Phase 2 Withdrawn
NCT00004114 2020-07-31
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer
Jonsson Comprehensive Cancer Center
Phase 1 Withdrawn
NCT04093648 2020-05-20
T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR)
Baylor College of Medicine
Phase 1 Withdrawn
NCT02274506 2020-01-22
Infusion of Allogeneic, 3rd Party CD19-specific T Cells
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT00006451 2020-01-03
Bone Marrow Transplantation in Treating Patients With Leukemia
Masonic Cancer Center, University of Minnesota
Phase 3 Withdrawn
NCT03935347 2020-01-02
Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy
Roswell Park Cancer Institute
Phase 2 Withdrawn
NCT03575234 2019-08-28
Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer
Emory University
Phase 1 Withdrawn
NCT02948101 2019-03-12
PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT02863913 2019-03-06
PD-1 Knockout Engineered T Cells for Muscle-invasive Bladder Cancer
Peking University
Phase 1 Withdrawn
NCT02867332 2019-03-06
PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma.
Peking University
Phase 1 Withdrawn
NCT02867345 2019-03-06
PD-1 Knockout Engineered T Cells for Castration Resistant Prostate Cancer
Peking University
Withdrawn
NCT03531281 2018-12-07
Human Lysozyme Goat Milk in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
City of Hope Medical Center
Phase 1 Withdrawn
NCT02538926 2018-11-14
Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
University of Washington
Phase 2 Withdrawn
NCT03285607 2018-08-16
MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer
Washington University School of Medicine
Phase 1 Withdrawn
NCT02702960 2018-06-15
Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Withdrawn
NCT00006123 2018-05-16
Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer
Dana-Farber Cancer Institute
Phase 1/2 Withdrawn
NCT02985333 2018-05-14
Paclitaxel,Cyclophosphamide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Sun Yat-sen University
Phase 2 Withdrawn
NCT03100877 2017-12-13
Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma
City of Hope Medical Center
Phase 1/2 Withdrawn
NCT01163201 2017-12-02
T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies
Masonic Cancer Center, University of Minnesota
Phase 1/2 Withdrawn
NCT01639456 2017-12-02
CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploid Donor Natural Killer Cell Treatment in Older AML in First Complete Remission
Masonic Cancer Center, University of Minnesota
Phase 2 Withdrawn
NCT01677949 2017-12-02
Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute Leukemia
Masonic Cancer Center, University of Minnesota
Phase 2 Withdrawn
NCT02118311 2017-12-02
Treg Cells for AGVHD in Non-myeloablative UCB Transplant
Masonic Cancer Center, University of Minnesota
Phase 2 Withdrawn
NCT00983944 2017-11-30
Rituximab and Combination Chemotherapy With or Without Bleomycin Sulfate in Treating Patients With Primary Mediastinal Large B-Cell Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 2 Withdrawn
NCT00005998 2017-11-29
Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
Masonic Cancer Center, University of Minnesota
Phase 2 Withdrawn
NCT01833767 2017-08-24
Low-dose Cyclophosphamide and Outpatient IV Interleukin-2 in Metastatic Melanoma
Western Regional Medical Center
Phase 2 Withdrawn
NCT03191981 2017-08-24
MUKfourteen
University of Leeds
Phase 1/2 Withdrawn